Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (1868)	3/3/2016 9:53:50 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Elaborate what? PR or "Las Vegas" bet? Without this sentence: <Regeneron currently has an angiopoeitin-like 3 (ANGPTL3) antibody, known as evinacumab or REGN1500, in clinical development. ANGPTL4 and ANGPTL3 are thought to be related inhibitors of LPL..> PR would be OK. Discovery of the interesting "lost of function mutation" that is warrant further investigation. However, how long it take to enroll 8 HoFH pts in 1500 P2 trial? One, two, three...five years? So, candidate (that come out of this RGC efforts) significantly diminish VALUE reported? Was it necessary, or was a promotion PR (HYPE) that will be follow by some "not so good news"??? Judge by itself. RGC is effort that should be respected. It will (I hope), in time, generate value for REGN shareholders. When there is good candidate that is results of this efforts investors will appreciate it. Until that time..I would live any "promotional" PR for silent period. Miljenko